Amarillo Pharmacy Compounding-Oncology
Awarded on January 22, 2026. Full description on SAM.gov.
Overview
- Posted
- January 22, 2026
- Notice type
- Award Notice
- Set-aside
- No Set aside used
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Veterans Affairs
Notice details
- Office
- 257-NETWORK CONTRACT OFFICE 17 (36C257)
- Place of performance
- 79106
- Last updated
- Nov 4, 2026
- First published
- Last updated on SAM.gov
- Award date
- Jan 22, 2026
- Award amount (SAM.gov award notice)
- $225.0K
Identifiers
- Solicitation number
- 36C25726D0022-36C25726N0093
- Notice ID
- c7ae3d75124841c9a085d088254088c7
- Award number (PIID)
- 36C25726D0022
Description
This was a competitive award not set aside because market research did not support a set aside. No small businesses responded. This is actually a modification (#P00001) for increase from the original award of $100,000 to $225,000.00 by $125,000. This is a contingency contract for pharmacy comounding for oncology medication for Veterans.
Award Overview
Award Number
36C25726D0022
Award Amount (SAM.gov award notice)
$225.0K
Award Date
Jan 22, 2026
Awardee
Awardee UEI
RN5UVE9XMJN4
Awardee CAGE Code
9HGM2
Awardee Address
Chandler, AZ 85226, UNITED STATES
Delivery Order Number
36C25726N0093
Line Item Number
0001
Original Solicitation
Notice ID: c7ae3d75124841c9a085d088254088c7
Posted Date: Jan 22, 2026
Original Response Deadline: Not specified
Task Orders Under This IDV
Top 10 by total obligated
- $225.0KSigned Oct 27, 2025
- $225.0KSigned Mar 10, 2026
- $225.0KSigned Jan 22, 2026
- $100.0KSigned Oct 20, 2026
More From This Vendor
Top 5 most recent
- $20.0KSigned Oct 23, 2026
- $100.0KSigned Oct 20, 2026
- $1.2MSigned Oct 7, 2026
- $350.0KSigned Oct 1, 2026
- $396.0KSigned Oct 1, 2026
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
VA Amarillo - modification 36C25726D0022 36C25726N0093 P00001_FE.pdf
287 KBAdded in Award Notice version 3Posted
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
Amarillo Pharmacy Compounding-Oncology
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Central Alabama Veterans Healthcare System Radiopharmaceuticals | 54% | Special Notice | 09/15/2026 |
QUESTIONS AND ANSWERS Q: Please clarify whether prescription drug ingredient costs reimbursed to participating retail pharmacies are considered pass-through costs or included in the 50% limitations on subcontracting calculation, and whether pharmacy dispensing fees are treated differently. A: This procurement is a services contract subject to the limitations on subcontracting requirements in VAAR 852.219-75. Prescription drug ingredient costs reimbursed to participating retail pharmacies are considered pass-through/direct reimbursement costs and are not considered service performance costs for purposes of the 50% subcontracting calculation. Pharmacy dispensing fees, however, are compensation for pharmacy services performed and are included in the limitations on subcontracting analysis unless performed by a similarly situated certified SDVOSB subcontractor. Offerors remain responsible for ensuring compliance with all applicable SBA and VA limitations on subcontracting requirements. | 45% | Solicitation | 11/23/2026 |
This is a PRE-SOLICITATION NOTICE ONLY. This is not a request for proposal, quotation, or bid. The Network Contracting Office 15 (NCO15), 3450 S 4th Street | Leavenworth, KS 66048 intends to issue a solicitation for a VOSB/SDVOSB set-aside, single award, Indefinite Delivery/indefinite Quantity Contract. The contract will cover the contractor provided third party pharmacy benefit services to support a First Fill Prescription Voucher Program serving eligible Veterans. This program provides first or urgent fill prescriptions when VA pharmacies are unable or impractical to dispense medications, such as after hours emergency room visits, time sensitive medications from Community Based Outpatient Clinics (CBOCs), Home Based Primary Care (HBPC), or telehealth appointments. The NAICS Code is 524292 Pharmacy Benefit Management and Other Third-Party Administration of Insurance and Pension Funds, NAICS Size Standard $4.5million. The Product Service Code is Q517 Pharmacy Services. All potential vendors MUST be registered and active in the SAM. SDVOSB/VOSB vendors must be registered in the SBA VetCert database. The solicitation will be issued electronically and will be available only via the Contract Opportunities / System for Award Management website www.sam.gov. No fax bid packages shall be accepted. The solicitation will be publicized on or about November 1st, 2026. No phone, fax or email inquiries will be taken for this Pre-Solicitation Notice | 44% | Pre-Solicitation | 11/16/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 43% | Solicitation | 11/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | 43% | Solicitation | 12/07/2026 |
Additional Details
Solicitation Number
36C25726D0022-36C25726N0093
Archive Date
Feb 6, 2026
Office Address
San Antonio, TX, 78240